Pharma Capital

Innate Immunotherapeutics to receive cash injection

The halt will remain in place until Monday 20th March 2017.
money_on_financial_documents,_sized_58c9d2696a7a4.png
The raising will involve a book build process

Innate Immunotherapeutics (ASX:IIL) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Innate requested the halt pending a capital raising.

The halt will remain in place until the opening of trade on Monday 20th March 2017, or earlier if an announcement is made to the market.

View full IIL profile

Innate Immunotherapeutics Timeline

View All

Related Articles

test tubes in a laboratory
It’s hived off its skin division, bolstered its board and has already won new business contracts worth €5.7mln so far this year

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.